Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Neuroendocrine Tumor (NET) Treatment Market

Neuroendocrine Tumor (NET) Treatment Market Share

Report ID: GMI10357
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Neuroendocrine Tumor Treatment Market Share

The competitive landscape of the market is characterized by the presence of several key players and a high degree of innovation driven by advancements in biotechnology and pharmaceuticals. Major companies such as Novartis AG, Pfizer Inc., and Ipsen Pharma are at the forefront, offering a range of treatment options including somatostatin analogs and targeted therapies. The market is witnessing increased investment in research and development to improve existing therapies and discover novel treatments, with a strong focus on enhancing efficacy and reducing side effects. Strategic collaborations, mergers, and acquisitions are common as companies aim to expand their portfolios and market reach.

Neuroendocrine Tumor Treatment Market Companies

Prominent players operating in the neuroendocrine tumor treatment industry include:

AVEO Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb
Eli Lilly & Company
F. Hoffmann-La Roche Ltd.
Hutchison MediPharma Limited
Ipsen
Jubilant Life Sciences Ltd.
Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
Novartis AG
Pfizer Inc.
Tarveda Therapeutics

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global neuroendocrine tumor (NET) treatment industry was valued at USD 2.5 billion in 2023 and is anticipated to register 9.1% CAGR between 2024 and 2032, fueled by the rising global incidence of NETs and the increasing technological advancements.

The hospitals & clinics segment is anticipated to reach USD 2.8 billion by 2032 due to their advanced infrastructure, comprehensive healthcare services, and access to cutting-edge diagnostic and therapeutic technologies.

North America neuroendocrine tumor treatment market is anticipated to reach USD 2.3 billion by 2032 due to the high prevalence of cancer and strong regulatory framework.

AVEO Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Hutchison MediPharma Limited, Ipsen, and Jubilant Life Sciences Ltd., among others.